Ceplene encounters obstacles on the rocky road to FDA approval.
Piascik
P
P
College of Pharmacy, University of Kentucky, Lexington, USA.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D017277:Drug Approval; D015507:Drugs, Investigational; D006632:Histamine / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D014481:United States; D014486:United States Food and Drug Administration
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D000998:Antiviral Agents; D015507:Drugs, Investigational; D006632:Histamine